IASO Bio Reports Early Responses in 10-Patient In Vivo CAR-T Study IASO Bio reported a 90% response rate in the first 10 evaluable multiple-myeloma patients treated with...

https://www.narrowit.com/news/iaso206-first-in-human-in-vivo-car-t-data-2026-09-27
#IasoBio #IASO206 #CART #MultipleMyeloma